Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10528 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-02-28

Study Completion Date

2018-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This population-based descriptive study will characterize first-time users of three NOACs (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial fibrillation (SPAF) patients and will assess the patterns of drug utilization in routine general practice in Colombia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea

NCT03572972

Atrial Fibrillation

COMPLETED

Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia

NCT04234698

Atrial Fibrillation

COMPLETED

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

NCT04297150

Atrial Fibrillation

UNKNOWN

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

NCT02470767

Stroke Prevention and Control Atrial Fibrillation

COMPLETED

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

NCT04249401

Atrial Fibrillation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SPAF patients in Colombia_Rivaroxaban

First time users of rivaroxaban in the Audifarma database

Data Collection

Intervention Type OTHER

Data will be extracted from July 2009 to the last available database extraction

SPAF patients in Colombia_Dabigatran

First time users of dabigatran in the Audifarma database

Data Collection

Intervention Type OTHER

Data will be extracted from July 2009 to the last available database extraction

SPAF patients in Colombia_Apixaban

First time users of apixaban in the Audifarma database

Data Collection

Intervention Type OTHER

Data will be extracted from July 2009 to the last available database extraction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data Collection

Data will be extracted from July 2009 to the last available database extraction

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* First prescription of NOACs (rivaroxaban, dabigatran and apixaban) in the outpatient setting.
* Non valvular Atrial Fibrillation (NVAF) Patients
* aged ≥18 years
* at least one year of enrollment in the Audifarma database
* one year since first encounter with healthcare provider will be included in the study

Exclusion Criteria

* Patients with any record of index drug prescription prior to the enrolment period.
* Patients who qualify as members of more than one cohort study on the same day

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No